about
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic ReviewEuropean union standards for tuberculosis careRecent developments in the diagnosis and management of tuberculosis.Tuberculosis control in prisons: current situation and research gapsIs there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patientsNew anti-tuberculosis drugs and regimens: 2015 updateTuberculosis elimination: theory and practice in Europe.Breaking the barriers: Migrants and tuberculosis.Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement.Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.Towards tuberculosis elimination: an action framework for low-incidence countriesTuberculosis treatment and drug regimens.Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomesA new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.The multidrug-resistant tuberculosis threat: old problems and new solutionsComparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data.Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control.Multidrug- and extensively drug-resistant tuberculosis, Germany.Epidemiology and clinical management of XDR-TB: a systematic review by TBNET.Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives.Drug-resistant tuberculosis: past, present, future.Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa.Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs.Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis.Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.Management of drug resistantTB in patients with HIV co-infection.Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences.Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?Classifying new anti-tuberculosis drugs: rationale and future perspectives.WHO strategies for the programmatic management of drug-resistant tuberculosis.Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
P50
Q26764847-EB4474AA-A637-43A1-B9D8-F77E51D3BEE4Q26823223-332BFA31-A923-4BCD-9796-6E975C5DD4BEQ28077124-C1236616-720D-4453-B5EF-EC99D32E4775Q28084044-11817658-FD3E-4A14-9BC3-463DFAF9554EQ28393235-9ADD0021-E818-40BF-8EA7-0C7949D30300Q28482730-17B670DC-E3CD-4A2D-B5B4-D9562EE5E33CQ28596775-9B543DEC-39FF-4773-B773-7DB4742FA0DDQ30217483-9EE2ED6F-4EBD-46BA-8485-5DC134BF6958Q30235452-AF040B83-4436-4AD0-B0F3-DD6068AFCCC2Q30236048-89249D02-F707-40A4-9B2F-3148BB5B2C14Q30527848-E72245BE-5C3C-4A1D-B763-42BA6D2FCFE1Q30573127-006453D4-DEBF-4E43-8AC6-AAB659578F18Q33383681-DC8DA4ED-4771-4C94-A501-E3A520CF620DQ33400720-5C0BB516-727C-42D1-8A61-2978156F23CCQ33440791-6BD0DAA7-3BBD-40A2-AE62-CD8BC41DE969Q35344151-5B1D68DB-70AA-42E7-8E78-938B52E90413Q35663866-4CFF360E-9A50-4D62-83C5-8BF214C4F387Q35805940-D4504DAA-EADF-489B-AA79-AD093BA49C9AQ35909311-1F83A3D4-46CB-449E-B8C7-DF405711BF99Q36094215-A5145A6B-6CE5-48C1-9944-EDBB300FE029Q36138237-37B4C2D1-7F30-46D7-89AB-408D7BA9887EQ36237568-E42B76E5-C22A-4447-B8A0-4212724A8C3DQ36288667-653BAE3D-A522-4708-86BE-AB550ACE6B9DQ36960077-6180AD3C-E338-43AB-8FB7-95DCACEE2CB6Q37072346-26184030-947B-4FFB-A165-45305A83A27AQ37404273-1673E469-42F1-49C7-8DB9-2B1F7027E69EQ37687828-B699CA21-9BC7-4366-BDC2-C65303057FDDQ37718949-3A613DAB-A9A1-4C78-9B08-98ECC912A392Q37764909-1B741150-A890-4A6C-A9BE-7693DE8AE8E5Q37990385-73542EB4-8EC0-4B92-9810-50F5C098CF67Q38062505-8621F97F-64A6-4417-8DBF-67E70CE9F6A7Q38063966-C9577B52-FD3C-4035-9F43-23FC3D79CDC4Q38341918-B89FE55B-83D6-4577-A57A-E3C4839EB156Q38378992-3C055520-B883-4E7D-B7C0-FE0BB161E37EQ38610637-AAB4FA10-BC53-4A8D-BFEB-3E3EEBCD11D4Q38716752-C948C593-72AA-41EC-B75B-F7CCA88D6F0EQ38787379-497D4674-ACCF-4CFA-A654-43D7B7E0E7EDQ38798034-09941E72-E8EE-4457-8EA8-D4C60A32C2ACQ38856343-EDE7987F-675E-4CAA-89BC-FE7C920DE4D5Q38915347-934D1295-0A11-47FE-A06B-F728C955652D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
R Centis
@ast
R Centis
@en
R Centis
@es
R Centis
@nl
R Centis
@sl
type
label
R Centis
@ast
R Centis
@en
R Centis
@es
R Centis
@nl
R Centis
@sl
altLabel
Rosella Centis
@en
prefLabel
R Centis
@ast
R Centis
@en
R Centis
@es
R Centis
@nl
R Centis
@sl
P106
P31
P496
0000-0002-8551-3598